02/10/22 8:30 AMNasdaq : LNTH conferencesearningsLantheus Holdings to Host Fourth Quarter and Full Year 2021 Earnings Conference Call and Webcast on February 24, 2022 at 8:00 a.m. Eastern TimeLantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, February 24, 2022, to discuss its financial and operating results for the fourth quarterRHEA-AIneutral
01/27/22 8:30 AMNasdaq : LNTH clinical trialLantheus Collaborates with The Prostate Cancer Clinical Trial Consortium (PCCTC) To Advance AI-Enabled Imaging Biomarkers in Prostate CancerLantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced that its subsidiary, EXINI Diagnostics AB (EXINI), has entered into a collaboration with the Prostate Cancer Clinical Trials Consortium (PCCTC) to advance artificial intelligenceRHEA-AIvery positive
12/01/21 8:30 AMNasdaq : LNTH managementLantheus Appoints Vivian Yao as Chief Human Resources OfficerLantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and followRHEA-AIpositive
11/29/21 8:30 AMNasdaq : LNTH Lantheus Announces PYLARIFY AI™ is Now AvailableLantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated providerRHEA-AIneutral
11/22/21 8:30 AMNasdaq : LNTH Lantheus Announces CMS Grants Transitional Pass-Through Payment for PYLARIFY® (piflufolastat F 18) Injection, Effective January 1, 2022Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committedRHEA-AIvery positive
11/17/21 8:30 AMNasdaq : LNTH Lantheus Holdings Announces Presentations Featuring PYLARIFY® (Piflufolastat F 18), its PSMA-Targeted Prostate Cancer Imaging Agent, at Key Scientific MeetingsLantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and followRHEA-AIneutral
11/16/21 4:30 PMNasdaq : LNTH conferencesLantheus Holdings to Present at the 4th Annual Evercore ISI HealthCONx ConferenceLantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and followRHEA-AIneutral
11/04/21 7:00 AMNasdaq : LNTH earningsLantheus Holdings, Inc. Reports Third Quarter 2021 Financial ResultsWorldwide revenue of $102.1 million for the third quarter 2021, representing an increase of 15.3% from the prior year period GAAP net loss of $13.4 million for the third quarter 2021, compared to GAAP net loss of $6.4 million in the prior year period GAAP fully diluted net loss of $0.20 for theRHEA-AIneutral
10/28/21 4:30 PMNasdaq : LNTH conferencesLantheus Holdings to Present at Upcoming Investor ConferencesLantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and followRHEA-AIneutral
10/21/21 8:00 AMNasdaq : LNTH conferencesearningsLantheus Holdings to Host Third Quarter 2021 Earnings Conference Call and Webcast on November 4, 2021 at 8:00 a.m. Eastern TimeLantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 4, 2021, to discuss its financial and operating results for the third quarter ofRHEA-AIneutral